Innate Pharma Highlights Lacutamab at Analyst and Investor Event

Innate Pharma SA will host an analyst and investor event on October 28, 2025, in New York City, focusing on lacutamab. This key compound for the company is progressing toward accelerated approval to treat Sézary syndrome, a type of cutaneous T-cell lymphoma (CTCL). The event will feature presentations on clinical studies, including promising results from the Phase 2 TELLOMAK trial, unveiled by Dr. Pierluigi Porcu, a T-cell lymphoma specialist.

ZS Associates, a renowned firm, will present data on the target population in the United States. Innate management will discuss progress in the Phase 3 trial and regulatory strategies. Lacutamab, which already has several regulatory designations, could offer a new therapeutic option for patients.